603207.SH上海证券交易所 · 主板 Main
Xiao Fang Pharma 小方制药
Chemical Pharmaceuticals 化学制药
¥24.25−¥0.59 · −2.38%
Open 开盘
¥24.70
High 最高
¥24.98
Low 最低
¥24.25
Prev Close 昨收
¥24.84
Volume 成交量
261.7万股
Turnover 成交额
¥6,414.8万
Mkt Cap 总市值
¥39亿
P/E 市盈率
20.4×
Recent Activity 近期动态All Filings 全部公告 →
28 significant filings since 29 May 2026: 3 on regulatory inquiry, 14 on equity incentive and 6 on share issue, and 3 other kinds. The latest, on 27 Aug 2026: 关于2026年中期利润分配方案的公告. 1 unverified report logged, the latest on 3 Sep 2026.
自 29 May 2026 起有 28 份重大公告：regulatory inquiry 3 份、equity incentive 14 份、share issue 6 份，另有 3 类。最新一份（27 Aug 2026）：关于2026年中期利润分配方案的公告。记录了 1 条未经核实的报道，最新一条见于 3 Sep 2026。
24.0025.0026.0027.00
Volume 成交量
1,579.9万
26 Aug02 Sep09 Sep17 Sep24 Sep
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥39亿 | ¥63亿 | 47th lowest of 158 · 158 家中第 47 低 | |
| Trailing P/E 市盈率 | 20.4x | 38.6x | 28th lowest of 112 · 112 家中第 28 低 | |
| P/B 市净率 | 3.4x | 2.5x | 54th highest of 157 · 157 家中第 54 高 | |
| Revenue Growth 营收增速 | 4.5% | 1.6% | 67th highest of 156 · 156 家中第 67 高 | |
| Profit Growth 净利增速 | -12.6% | 1.9% | 63rd lowest of 158 · 158 家中第 63 低 | |
| Gross Margin 毛利率 | 60.9% | 50.2% | 47th highest of 155 · 155 家中第 47 高 | |
| Net Margin 净利率 | 37.4% | 9.8% | 9th highest of 157 · 157 家中第 9 高 | |
| Return on Equity 净资产收益率 | 9.3% | 3.1% | 12th highest of 157 · 157 家中第 12 高 | |
| Debt to Assets 资产负债率 | 12.5% | 28.0% | 27th lowest of 158 · 158 家中第 27 低 | |
| Grade Score 评级得分 | 73 | 51 | 11th highest of 157 · 157 家中第 11 高 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,979亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,977亿 | 38.5x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥699亿 | 73.7x | 14.3x | 54.7% | 27.5% | 18.3% | B |
| CSPC Innovation Pharmaceutical 石药创新 | ¥620亿 | 60.6x | 15.8x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥618亿 | 33.8x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Fosun Pharma 复星医药 | ¥610亿 | 18.0x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| Innocare 诺诚健华 | ¥528亿 | 57.5x | 6.9x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥469亿 | 17.5x | 5.5x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥457亿 | 13.2x | 1.8x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥337亿 | 50.0x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥293亿 | 34.5x | 4.5x | -11.4% | 10.8% | 8.1% | D |
| Zelgen 泽璟制药 | ¥288亿 | 52.5x | 16.8x | 220.9% | 53.1% | 45.7% | B |
| Dizal Pharmaceutical 迪哲医药 | ¥263亿 | — | 23.2x | 47.2% | -40.8% | -17.2% | D |
| Xiao Fang Pharma 小方制药 | ¥39亿 | 20.4x | 3.4x | 4.5% | 37.4% | 9.3% | B |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。